← Back to Search

Unknown

CBP-201 for Chronic Rhinosinusitis

Phase 2
Waitlist Available
Research Sponsored by Suzhou Connect Biopharmaceuticals, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to week 32
Awards & highlights

Study Summary

This study is evaluating whether a drug may help treat chronic sinusitis.

Eligible Conditions
  • Chronic Rhinosinusitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to week 32
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to week 32 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Average Daily Nasal Congestion Score (NCS)
Change in Endoscopic Nasal Polyp Score (NPS)
Secondary outcome measures
Change From Baseline in Blood Level of IgE
Change From Baseline in Eosinophil Cationic Protein (ECP)
Change From Baseline in Eotaxin-3
+12 more

Side effects data

From 2021 Phase 2 trial • 226 Patients • NCT04444752
12%
Dermatitis atopic
7%
COVID-19
7%
Urinary tract infection
5%
Headache
4%
Conjunctivitis
2%
Upper respiratory tract infection
2%
Vomiting
2%
Nausea
2%
Nasopharyngitis
2%
Eye pruritis
2%
Injection site reaction
2%
Pruritis
100%
80%
60%
40%
20%
0%
Study treatment Arm
CBP-201 150 Q2W
CBP-201 300 Q2W
Placebo
CBP-201 300 Q4W

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: CBP-201 Dose 2Experimental Treatment1 Intervention
CBP-201 Dose 2 subcutaneous (SC) injection.
Group II: CBP-201 Dose 1Experimental Treatment1 Intervention
CBP-201 Dose 1 subcutaneous (SC) injection.
Group III: PlaceboPlacebo Group1 Intervention
Placebo subcutaneous (SC) injection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBP-201
2020
Completed Phase 2
~880

Find a Location

Who is running the clinical trial?

Suzhou Connect Biopharmaceuticals, Ltd.Lead Sponsor
10 Previous Clinical Trials
1,889 Total Patients Enrolled
Suzhou ConnectStudy DirectorSuzhou Connect Biopharmaceuticals, Ltd.
10 Previous Clinical Trials
1,899 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
2021. "A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04783389.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top